Jianfeng Group Lin2015 -021 (School-Enterprise Strategic Cooperation Agreement)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: Pro 2015-021
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Signing a School-Enterprise Strategic Cooperation Agreement with Guangxi Medical University
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
1. Basic Information
Recently, Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Jianfeng Group" or "Company") and Guangxi Medical University signed the "School-Enterprise Strategic Cooperation Agreement" (hereinafter referred to as the "Agreement"). Adhering to the tenet of "mutual benefit, complementary advantages, collaborative cooperation and common progress", the two sides establish and develop friendly strategic cooperative relations, and further gather the strength of universities and enterprises by integrating the resources of both sides. promote the common development of schools and enterprises.
Main Contents of 2. Agreement
Party A: Guangxi Medical University
Party B: Zhejiang Jianfeng Group Co., Ltd.
Main Contents of (I) Cooperation
Market-oriented, both parties actively carry out all-round cooperation in production, education and research; Party A gives full play to its advantages in medical education, research and development, and medical resources, provide Party B with services such as talent information, new drug research and development, technical research and clinical research; Party B will give priority to Party A's cooperation in the above fields and actively promote school-enterprise cultural exchange activities.
(II) Party A's rights and obligations
1 . Party A shall timely inform Party B of the resource information of students and graduates in school to provide services for Party B's talent needs.
2 , Party A relies on the scientific research strength of experimental equipment and teachers in colleges and universities, actively carries out scientific research cooperation with Party B, carries out project research in the way of project management, and provides various social services such as new drug research and development, technical research and other aspects for the pharmaceutical enterprises affiliated to Party B.
3 . Medical institutions affiliated to Party A actively provide new drug clinical trials for pharmaceutical enterprises affiliated to Party B.
4 . Under the same conditions, the medical institutions under Party A shall give priority to the products of the pharmaceutical enterprises under Party B.
(III) Party B's rights and obligations
1 . Both parties cooperate to carry out diversified school-enterprise cultural exchange activities, and Party B shall provide active cooperation and necessary support.
2 . Party B shall timely inform Party A of the talent demand information of the enterprise, and conduct talent supply and demand information docking activities from time to time, such as special talent recruitment meetings. Under the same conditions, priority shall be given to the graduates of Party A.
3 . Party B actively carries out industry-university-research cooperation with Party A. Relying on Party A's scientific research platform, Party B gives priority to relevant cooperation with Party A.
4 , Party B actively participates in the mixed ownership reform of Party A's subordinate enterprises, and enjoys the priority of Party A's scientific research achievements transfer and business cooperation with Party A's subordinate medical institutions.
Impact of 3. on Company
Guangxi Medical University was founded on November 21, 994 1934. It is one of the key universities in Guangxi. It is the center of medical education, medical research, clinical medical treatment and preventive health care in Guangxi. It has rich medical education and research and development resources . The company can rely on its advantages in pharmaceutical education, research and development, and medical resources to provide the company with talent information, new drug research and development, technical research, and clinical research. The strategic partnership between the two parties will have a positive impact on the company's pharmaceutical industry. 4. Reference Document
"School-Enterprise Strategic Cooperation Agreement"
hereby announces
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 26, 2015
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page